Cite
HARVARD Citation
Sobrero, A. et al. (n.d.). 2118 Quality of life (QoL) during second-line treatment with FOLFIRI +/- panitumumab (pmab) in patients (pts) with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC). European journal of cancer. pp. S369-S370. [Online].